Xencor Corp - XNCR Net earnings per share for the last four quarters

Official company branding of Xencor Corp (XNCR)

Xencor, Inc. (XNCR) profit dynamics are based on the development of antibodies to combat oncology and autoimmune pathologies. The YoY EPS growth rate (trailing 12 months) illustrates the impact of the protein engineering platform for pharma behemoths, as well as the stability of royalties from licensees. The current 11.30 indicator shows the value of this parameter, confirming the resilience of the company's operating model within the immuno-oncology sector.

Xencor (XNCR) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026

XNCR (Xencor): analytical breakdowns and indicator data

- current price and projected stock value:
Initial company analysis:XNCR, Xencor Corp
Mass-produced product of xencor.com

Amidst a fierce battle against industry behemoths to establish itself as the standard in cancer immunotherapy, Xencor, Inc. must demonstrate high efficiency in capitalizing on its developments. The trailing twelve-month (TTM) earnings per share dynamics compared to last year allow for a real-time assessment of business profitability relative to the sector, which is clearly reflected in the annual EPS growth rate (ttm).

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months